-transparent.png){kind=logo}
When 0.5 microgram of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) per ml was incorporated directly into cell culture medium inoculated with eight known positive specimens, one herpes simplex virus type 1 (HSV-1) isolate grew in the presence of BVdU and was misidentified. By plaque assay, the titers of 15 HSV-1 strains were reduced by more than 3 log10 by BVdU, and the titers of 16 HSV-2 strains were reduced by less than 2 log10. Titers of HSV-1 acyclovir-resistant strains were reduced by less than 1.5 log10, which was characteristic of HSV-2 strains. Thus, typing of HSV isolates in the presence of BVdU by plaque assay is reliable only if information regarding previous antiviral therapy is obtained.
E M Swierkosz, and
M Q Arens, and
K A Rivetna
January 1991,
Intervirology,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
September 1982,
Antimicrobial agents and chemotherapy,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
April 1995,
Acta virologica,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
January 1980,
Antimicrobial agents and chemotherapy,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
June 1985,
Antiviral research,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
April 1987,
Molecular pharmacology,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
November 1984,
Antimicrobial agents and chemotherapy,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
April 1982,
Journal of clinical microbiology,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
June 1982,
The Journal of infectious diseases,
E M Swierkosz, and
M Q Arens, and
K A Rivetna
May 1984,
Antimicrobial agents and chemotherapy,
